BSH 2020 Virtual Industry Symposia
We are delighted to include a vast array of industry-led symposia available to view on demand or live as part of the BSH 2020 Virtual Conference programme.
The following 60-minute symposia will be available from 09:00 on Monday 9 November.
The premium symposia will also be available to view at a scheduled broadcast time with an opportunity to put your questions to the faculty during the live 30 minute Q&A session.
Premium Symposia Programme
| Industry Partner | Day/Time | Symposium Details |
|---|---|---|
| Tuesday 10 November | ||
|
Symposium 08:00 - 09:30 | Reframing possibilities in relapsed and refractory multiple myeloma
Speakers Chair: Prof Graham Jackson Dr Ceri Bygrave Dr Charlotte Pawlyn Dr Karthik Ramasamy Prof Kwee Yong |
|
Symposium 12:30 - 14:00 | Updates in VTE management
This meeting is intended for UK healthcare professionals only. In this promotional symposium, organised and funded by Pfizer Ltd on behalf of the BMS/Pfizer Alliance, our expert faculty will discuss the recently updated NICE guidelines on the diagnosis and management of VTE, whilst talking through the case of a patient who presents with signs and symptoms of pulmonary embolism. Join us as they discuss the rationale for the changes in guideline recommendations, as well as providing their own insights and experience during discussions on the implications for clinical practice. Following the presentation our faculty will open the floor to questions from the audience during the live Q&A session. For Prescribing and Adverse Event reporting information, click here This meeting has been organised and funded by Pfizer Ltd on behalf of the BMS/Pfizer Alliance PP-ELI-GBR-7596 | October 2020 |
 |
Symposium 16:00 - 17:30 | The evolution of immune thrombocytopenia management in the UK
16:00 – 16:05 Welcome and introduction - Dr Drew Provan (Emeritus Reader in Autoimmune Haematology Barts and The London School of Medicine and Dentistry) 16:05 – 16:25 Updates to the International Consensus Report (ICR) and treating ITP in the COVID era - Dr Drew Provan 16:25 – 17:00 Living with immune thrombocytopenia (ITP) in the UK: A patient perspective - Jonny Mellor (Athlete and ITP patient champion Team New Balance, Manchester) and Steve Vernon (Coach Team New Balance, Manchester) 17:00 – 17:30 Audience Q&A Facilitated by Dr Drew Provan |
|
|
Symposium 16:00 - 17:30 | MPN Patient Management: A Real World Perspective |
| Wednesday 11 November | ||
 |
Symposium 12:30 - 14:00 | Covering all lines in CLL: Venclyxto (venetoclax) to trigger deep response
Welcome and Introduction Evolution of CLL Therapies – Anna Schuh Ven+O as a first-line treatment option for CLL – Anna Schuh Ven+R in R/R CLL: MURANO update and sequencing evidence – Dima El-Sharkawi Summary – Anna Schuh Live Q&A – all faculty |
| Thursday 12 November | ||
|
Symposium 08:00 - 09:30 | Controversies and Progress in T-Cell Lymphoma: including a preview of the 2021 BSH T-cell
guidelines T-cell lymphoma - a moving target – Dr Graham Collins Towards molecularly-guided therapy for TNHL – Dr Matthew Ahearne Guidelines Update – Controversies & Progress – Dr Chris Fox Challenging Clinical Cases - Ask the Experts – Prof Tim Illidge |
|
Symposium 12:30 - 14:00 | A new therapeutic approach in the management of relapsed/refractory follicular lymphoma
A new therapeutic approach in the management of relapsed/refractory follicular lymphoma Welcome and introduction – Prof John Gribben Management of R/R follicular lymphoma: current treatment options – Dr Will Townsend R2: a chemotherapy-free immunomodulatory combination for R/R FL (AUGMENT) – Prof John Gribben Live Q&A (15 minutes) – all faculty R2 in UK clinical practice: real world experience - Prof John Gribben and Dr Will Townsend Live Q&A (15 minutes) – all faculty |
|
|
Symposium 16:00 - 17:30 | The Current Treatment Paradigm for Treatment of Acute Myeloid Leukaemia |
 |
Symposium 16:00 - 17:30 | Castleman disease: Ongoing challenges and the pursuit of optimal patient care Are you looking for specialist insights and guidance on the treatment of Castleman disease (CD)? Then look no further. Please join us for our symposium, where valuable expert opinions will be provided by consultant haematologists Professor Steve Schey, Dr Matthew Streetly, Dr Jim Cavet and Dr Karthik Ramasamy. Sessions will discuss the disease spectrum, the difficulties of correctly diagnosing CD, the current treatment guidelines, and future aspirations for managing CD in the UK. To illustrate the challenges faced in clinical practice, real-world case studies will be used throughout the symposium. After the presentations, our expert faculty will join us live for a Q&A session, during which you will have the opportunity ask questions. This is a promotional symposium sponsored by EUSA Pharma. Medicines developed by EUSA Pharma will be discussed. Chair’s welcome - Professor Steve Schey Diagnosing CD: Challenges and considerations - Dr Matthew Streetly Treating iMCD: Current guidelines and perspectives - Dr Jim Cavet Looking to the future: Managing CD in the UK - Dr Karthik Ramasamy |
| Friday 13 November | ||
 |
Symposium 16:00 - 17:30 | CAR T in the UK: Achieving more together for our patients Introduction to meeting and brief overview of axicabtagene ciloleucel across Europe Chair: Prof. John Gribben Patient selection and care coordination in the UK - Dr Ram Malladi King’s data and case studies - Dr Robin Sanderson Q&A and panel discussion – Liza Loidolt |
The following symposia will be available to view on demand from 09:00 on Monday 9 November.
| Industry Partner | Symposium Details |
|---|---|
|
Patient-HCP Communication in Haematology |
 |
Tailoring Immune Thrombocytopenic Purpura (ITP) treatment based on the needs of individual patients and focussing on outcomes that matter to them |
 |
Reshaping the management of relapsed/refractory AML with targeted agents How are the challenges of AML management being addressed? - Professor Torsten Haferlach How are outcomes improving for FLT3-mutated R/R AML patients? - Professor Mark Levis Allograft for R/R FLT3-mutated AML - Dr Anne-Louise Latif |
 |
Chronic Lymphocytic Leukaemia (CLL) |
 |
Practical Experience with a New Treatment for Chronic ITP Overview of ITP Diagnosis & Treatment - James Bussel Review of Fostamatinib Clinical Data - Nichola Cooper Case Presentations - Ralph Boccia Panel Discussion |
 |
Updates in CML Research Results from an Interim Analysis of OPTIC - Prof Jane Apperley, Hammersmith Hospital, London The new gold standard for mutational analysis and CML treatment - Dr Hugues de Lavallade, King’s College Hospital, London MATCHPOINT study update - Prof Mhairi Copland, Beatson Cancer Centre, Glasgow |
 |
New Vyxeos Liposomal data |
 |
Innovation Session POLIVY®▼(polatuzumab vedotin)-bendamustine-rituximab patient case studies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Dr Wendy Osborne (Freeman Hospital) and Dr William Townsend (UCLH) discuss two own patient case studies with POLIVY®▼(polatuzumab vedotin)-bendamustine-rituximab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). For prescribing information and how to report adverse events, please click here. M-GB-00001695 & M-GB-00001694 October 2020. |
|
|
The Holmes and Watson Approach to Differential Diagnosis: Thrombocytopenia and
Anaemia
Welcome and introduction - Dr Richard Gooding Case 1: A surprising discovery in suspicious circumstances - Dr Haris Kartsios Case 2: Elements not Elementary, my dear Watson! - Dr Richard Gooding Concluding remarks and key take home messages - Dr Richard Gooding |
|
Multiple Myeloma – The Big Debate Chair: Professor Graham Jackson Dr Rakesh Popat, Dr Karthik Ramasamy, Ms Tanya Burton |